| [1] |
Xia Changfa, Dong Xuesi, Li He, et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108 .
|
| [2] |
Shen Jie, Liu Yajing, Liu Aihong, et al. Artificial intelligence-assisted ultrasound screening for breast cancer in China: A prospective, clustered, controlled, population-based study[J]. Breast Cancer Res, 2025, 27(1): 173. doi: 10.1186/s13058-025-02128-0 .
|
| [3] |
|
| [4] |
|
| [5] |
Torlakovic E E, Baniak N, Barnes P J, et al. Fit-for-purpose ki-67 immunohistochemistry assays for breast cancer[J]. Lab Investig, 2024, 104(7): 102076. doi: 10.1016/j.labinv.2024.102076 .
|
| [6] |
Tabnak P, Hajiesmailpoor Z, Baradaran B, et al. MRI-based radiomics methods for predicting ki-67 expression in breast cancer: A systematic review and meta-analysis[J]. Acad Radiol, 2024, 31(3): 763-787. doi: 10.1016/j.acra.2023.10.010 .
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
Yuan Quan, Ye Rongjie, Qian Yao, et al. Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer[J]. Ann Med, 2025, 57(1): 2541316. doi: 10.1080/07853890.2025.2541316 .
|
| [12] |
Burstein H J, Curigliano G, Gnant M, et al. Tailoring treatment to cancer risk and patient preference: The 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer[J]. Ann Oncol, 2025, 36(12): 1433-1446. doi: 10.1016/j.annonc.2025.09.007 .
|
| [13] |
Hamann M, Christgen M, Gluz O, et al. Endocrine response assessment in HR-positive HER2-negative early breast cancer: Concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)[J]. ESMO Open, 2025, 10(8): 105552. doi: 10.1016/j.esmoop.2025.105552 .
|
| [14] |
Mo Sijie, Luo Hui, Wang Mengyun, et al. Machine learning radiomics based on intra and peri tumor PA/US images distinguish between luminal and non-luminal tumors in breast cancers[J]. Photoacoustics, 2024, 40: 100653. doi: 10.1016/j.pacs.2024. 100653 .
|
| [15] |
Li Fang, Zhu Tongwei, Lin Miao, et al. Enhancing ki-67 prediction in breast cancer: Integrating intratumoral and peritumoral radiomics from automated breast ultrasound via machine learning[J]. Acad Radiol, 2024, 31(7): 2663-2673. doi: 10.1016/j.acra.2023.12.036 .
|
| [16] |
Huang Yini, Yao Zhao, Li Lingling, et al. Deep learning radiopathomics based on preoperative US images and biopsy whole slide images can distinguish between luminal and non-luminal tumors in early-stage breast cancers[J]. EBioMedicine, 2023, 94: 104706. doi: 10.1016/j.ebiom.2023.104706 .
|
| [17] |
Wu Jiangfeng, Ge Lifang, Jin Yun, et al. Development and validation of an ultrasound-based radiomics nomogram for predicting the luminal from non-luminal type in patients with breast carcinoma[J]. Front Oncol, 2022, 12: 993466. doi: 10.3389/fonc. 2022.993466 .
|
| [18] |
Zhou Jianan, Wu Jialing, Zhu Changfu, et al. Ultrasound radiomics in the assessment of breast cancer molecular subtypes: A systematic review and meta-analysis[J]. Med Ultrason, 2025, 27(3): 315. doi: 10.11152/mu-4449 .
|
| [19] |
Jiang Chun, Zhu Tong, Zong Yunfei, et al. Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer[J]. Front Surg, 2025, 12: 1697963. doi: 10.3389/fsurg.2025.1697963 .
|
| [20] |
Song S E, Cho K R, Cho Y, et al. Machine learning with multiparametric breast MRI for prediction of Ki-67 and histologic grade in early-stage luminal breast cancer[J]. Eur Radiol, 2022, 32(2): 853-863. doi: 10.1007/s00330-021-08127-x .
|
| [21] |
Crombé A, Kataoka M. Breast cancer molecular subtype prediction: Improving interpretability of complex machine-learning models based on multiparametric-MRI features using SHapley Additive exPlanations (SHAP) methodology[J]. Diagn Interv Imaging, 2024, 105(5): 161-162. doi: 10.1016/j.diii.2024.01.008 .
|
| [22] |
Ejiyi C J, Qin Zhen, Monday H, et al. Breast cancer diagnosis and management guided by data augmentation, utilizing an integrated framework of SHAP and random augmentation[J]. Biofactors, 2024, 50(1): 114-134. doi: 10.1002/biof.1995 .
|